Anti-CD19 CAR T-cell therapy (Southwest Hospital Chongqing)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-CD19 CAR T-cell therapy (Southwest Hospital Chongqing)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, Large B-Cell, DiffuseLymphomaLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesThe Southwest Hospital of AMU
China Registration ClassN/A

Develop Information

Active CompaniesThe Southwest Hospital of AMU
Inactive CompaniesN/A
Active IndicationsLymphoma, Large B-Cell, Diffuse
Inactive IndicationsLymphomaLeukemia

Other Information

ATC CodeN/A
Related LinksN/A